drugset / Trial / NCT02242643
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
Timeline
- Start
- 2014-10-01
- Primary completion
- 2015-03-16
- Completion
- 2015-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluLaval® Quadrivalent | Vaccine | — | Intramuscular |
| Comparator | Influenza Virus Vaccine | Vaccine | — | Intramuscular |